Gastric Cancer

Papers
(The median citation count of Gastric Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma689
Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemothe107
Predicting chemotherapy responsiveness in gastric cancer through machine learning analysis of genome, immune, and neutrophil signatures81
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plu71
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study64
Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer61
Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis43
Helicobacter pylori and gastric cancer: a lysosomal protease perspective38
Dose–response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis37
Risk prediction model for gastric cancer within 5 years in healthy Korean adults36
The putative pleiotropic functions of meprin β in gastric cancer35
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)35
Clinicopathological significance of microsatellite instability and immune escape mechanism in patients with gastric solid-type poorly differentiated adenocarcinoma35
Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer33
Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer32
FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer30
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma29
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study28
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape28
Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions27
Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape26
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)26
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast25
Comment on: Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study25
Outcomes after gastrectomy according to the Gastrectomy Complications Consensus Group (GCCG) in the Dutch Upper GI Cancer Audit (DUCA)25
LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer25
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 ra24
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-0724
FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL124
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach23
The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry23
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies23
Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study22
Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials22
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study21
Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-ce21
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients21
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-06121
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma21
Effect of preoperative chemotherapy on the histopathological classification of gastric cancer20
Effect of single-shot intrathecal morphine versus continuous epidural analgesia on length of stay after gastrectomy for cancer: a retrospective cohort study20
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer19
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences19
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model19
Development and application of deep learning-based diagnostics for pathologic diagnosis of gastric endoscopic submucosal dissection specimens19
Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells18
CAF promotes chemoresistance through NRP2 in gastric cancer18
Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer18
Numerous lesions of gastric adenocarcinoma of fundic-gland and fundic gland-mucosa type in a patient17
Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation17
SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy17
A systematic review on the effectiveness of robot-assisted minimally invasive gastrectomy17
International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study17
The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN16
Correction to: Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study16
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study16
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world16
Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice16
Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer16
TMEM205 induces TAM/M2 polarization to promote cisplatin resistance in gastric cancer16
Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma15
Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy15
Investigating the role of inflammatory cytokines in mediating the effect of gut microbiota on gastrointestinal cancers: a mendelian randomization study15
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study15
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials15
Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification15
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair15
Removal of small extracellular vesicles inhibits the progression of peritoneal dissemination in gastric cancer15
Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study15
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet 15
Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis15
Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ15
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)15
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer14
ATF4-mediated circTDRD3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-891b/ITGA2 axis and AKT signaling pathway14
Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations14
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE14
Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis14
A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)14
Leptomeningeal carcinomatosis in gastric cancer: A Review14
Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer14
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”13
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor13
Development and evaluation of a double-check support system using artificial intelligence in endoscopic screening for gastric cancer13
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer13
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)13
Comment on: “Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study. Gastric cancer, 2021 Aug 5” by Kim et al.13
Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014–2021: a retrospective study using open data from a national claims database13
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric 13
Reply to the letter to the editor regarding “Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ”12
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer12
Treatment response after palliative radiotherapy for bleeding gastric cancer: a multicenter prospective observational study (JROSG 17-3)12
The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-anal12
Complete one-to-one correspondence between magnifying endoscopic and histopathologic images: the KOTO method II11
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models11
Comment on:“Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema,” Gastric cancer, 2021 11
Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis11
N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X11
Safety and feasibility of single-incision laparoscopic distal gastrectomy in overweight and obese gastric cancer patients: a propensity score-matched analysis11
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer11
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer11
Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer11
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric juncti11
SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis11
Limitations of the cox proportional hazards model and alternative approaches in metachronous recurrence research11
A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer10
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib10
Minimum resection length to ensure a pathologically negative distal margin and the preservation of a larger remnant stomach in proximal gastrectomy for early upper gastric cancer10
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer10
Acknowledgment to Reviewers10
Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer10
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway10
Nishi memorial award in gastric cancer9
Cardiovascular and thromboembolic outcomes with immune checkpoint inhibitors in gastroesophageal cancer: a propensity score-matched cohort study9
Importance of duodenal stump reinforcement to prevent stump leakage after gastrectomy: a large-scale multicenter retrospective study (KSCC DELICATE study)9
Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors9
CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis9
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions9
IL-1β derived from mixed-polarized macrophages activates fibroblasts and synergistically forms a cancer-promoting microenvironment9
Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma9
Failure of evaluation on ABC classification for gastric cancer screening9
5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer9
Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset8
IL-17A promotes Helicobacter pylori-induced gastric carcinogenesis via interactions with IL-17RC8
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 68
Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction8
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)8
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action8
Racial disparities of gastric cancer in the USA: an overview of epidemiology, global screening guidelines, and targeted screening in a heterogeneous population8
Impact of early economic activity loss on all-cause mortality in gastric cancer survivors following curative treatment: a nationwide study in Korea8
The relationship between the gastric cancer microbiome and clinicopathological factors: a metagenomic investigation from the 100,000 genomes project and The Cancer Genome Atlas8
Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for advanced gastric cancer: exploratory analysis of the JCOG1001 phase III trial8
Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy8
Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody–drug conjugate development8
Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection?8
Trends in clinical outcomes and long-term survival after robotic gastrectomy for gastric cancer: a single high-volume center experience of consecutive 2000 patients7
Comparison of perioperative outcomes between bipolar sealing, ultrasonic shears and a hybrid device during laparoscopic gastrectomy for early gastric cancer: a prospective, multicenter, randomized stu7
A comparative study of demarcation line diagnostic performance between non-magnifying observation with white light and non-magnifying observation with narrow-band light for early gastric cancer7
Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study7
Recurrence of gastric cancer caused by implantation of tumor cells after percutaneous transesophageal gastrostomy7
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy7
Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer7
Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism7
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS7
Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination7
Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma7
Leukaemia inhibitory factor in gastric cancer: friend or foe?7
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world7
Comment on “Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohor7
LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA7
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial7
Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma7
Soluble factors in malignant ascites promote the metastatic adhesion of gastric adenocarcinoma cells7
Nishi memorial award in gastric cancer6
Molecular profile of poorly cohesive gastric carcinoma with special reference to survival6
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)6
Oncological impact of unexpected horizontal tumor spread in gastric cancer that requires total gastrectomy6
Circulating hormones and risk of gastric cancer by subsite in three cohort studies6
Global burden of young-onset gastric cancer: a systematic trend analysis of the global burden of disease study 20196
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)6
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study6
National guidelines for gastric cancer: redundant or needed?6
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis6
Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study5
Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer5
Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)5
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial5
Ubiquitination of ADRα1d/SerpinA1 complex stimulates hypoxia to induce gastric tumorigenesis with a combination of Helicobacter pylori and chronic stress through IL-1α5
Superior lymph node harvest by fluorescent lymphography during minimally invasive gastrectomy for gastric cancer patients with high body mass index5
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective5
The Magic Flute is a Singspiel, not an opera? My thoughts about the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer5
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial5
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach5
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 20235
Feasibility of intraoperative pathologic examination for sentinel lymph nodes during sentinel node navigation surgery in early gastric cancer: results of pathologic protocol for SENORITA trial5
Correction to: DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer5
The molecular profile of gastric intraepithelial foveolar type neoplasia based on somatic copy number alterations and multiple mutation analysis5
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?5
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy5
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study5
Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type5
Correction: An artificial intelligence system for comprehensive pathologic outcome prediction in early gastric cancer through endoscopic image analysis (with video)5
Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens5
Early stage gastric cancer with unusual sarcomatous component and no recurrence after endoscopic submucosal dissection: a case report5
Correction: Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis5
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy w5
Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based 5
Inhibition of proprotein convertases activity results in repressed stemness and invasiveness of cancer stem cells in gastric cancer5
Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study4
Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)4
Correction: Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer4
Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy: a propensity matching analysis4
A nonrandomized controlled trial: long-term outcomes of LATG/LAPG for cStage I gastric cancer: Japan Clinical Oncology Group Study JCOG14014
The occurrence, progression and development of four types of gastric mucosal atrophic lesions and their histopathological characteristics4
Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer4
Effects of RAD50 SNP, sodium intake, and H. pylori infection on gastric cancer survival in Korea4
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model4
Clinicopathological significance of JAK2, STAT3, and STAT4 expression in patients with gastric solid-type poorly differentiated adenocarcinoma: a retrospective study4
Dihydrotestosterone-androgen receptor signaling suppresses EBV-positive gastric cancer through DNA demethylation-mediated viral reactivation4
Multicenter phase II study on the efficacy of an oral nutritional supplement containing eicosapentaenoic acid in advanced gastric cancer patients with cachexia4
PD-L1 IHC testing: issues with interchangeability evidence based on laboratory-developed assays of unknown analytical performance4
Lipocalin-2 negatively regulates epithelial–mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancer4
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy w4
Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial4
CEACAM5 and TROP2 define metaplastic and dysplastic transitions in human antral gastric precancerous lesions and tumors4
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study4
YAP as a therapeutic target to reverse trastuzumab resistance4
Integrin β1 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells4
An artificial intelligence system for comprehensive pathologic outcome prediction in early gastric cancer through endoscopic image analysis (with video)3
Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer3
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study3
Collagen-related gene expression level predicts the prognosis and immune therapy response3
PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment3
Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry stomach cancer subcohort3
Correction: A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG13
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience3
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC16013
Evaluation of the widths of the mucosal strips in pathological examination of specimens of endoscopic submucosal dissection for early gastric cancer3
Direct prediction of genetic aberrations from pathology images in gastric cancer with swarm learning3
Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric ca3
Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer3
Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy3
CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma3
Correction to: DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial–mesenchymal transition in gastric cancer3
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy3
Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data3
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer3
Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma3
Impact of preoperative prealbumin levels on long-term prognosis in patients with gastric cancer after gastrectomy: a retrospective cohort study3
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial3
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells3
Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression3
Transformer-based skeletal muscle deep-learning model for survival prediction in gastric cancer patients after curative resection3
The oncogenic role of hypomethylated ZNF793 in gastric carcinoma: a focus on cell survival and stemness3
Reply to the letter by Junjie Jiang et al. regarding our manuscript “Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study”3
Short-term outcomes of preoperative computed tomography angiography versus standard assessment in patients with BMI ≥ 25.0 kg/m2 undergoing laparoscopic gastrectomy: the GISSG20-01 randomized clinical3
Improved survival after laparoscopic compared to open gastrectomy for advanced gastric cancer: a Swedish population-based cohort study3
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review3
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials3
0.070813894271851